CS1 targeted chimeric antigen receptor-modified T cells
US-10821161-B2 · Nov 3, 2020 · US
CS1 targeted chimeric antigen receptor-modified T cells
US11730797B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11730797-B2 |
| Application number | US-202016992361-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 13, 2020 |
| Priority date | Dec 5, 2014 |
| Publication date | Aug 22, 2023 |
| Grant date | Aug 22, 2023 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Chimeric antigen receptors for use in treating malignant melanoma and other cancers expressing CS1 are described.
First claim
Opening claim text (preview).
What is claimed is: 1. A chimeric antigen receptor (CAR) or polypeptide comprising the amino acid sequence of any of SEQ ID NOs: 29, 30, 31, 32, 33, 34, 38, 39, and 40. 2. The CAR or polypeptide of claim 1 , wherein the chimeric antigen receptor or polypeptide comprises the amino acid sequence of any of SEQ ID NOs: 29, 30, and 31. 3. The CAR or polypeptide of claim 1 , wherein the chimeric antigen receptor or polypeptide comprises the amino acid sequence of any of SEQ ID NOs: 32, 33, and 34. 4. The CAR or polypeptide of claim 1 , wherein the chimeric antigen receptor or polypeptide comprises the amino acid sequence of any of SEQ ID NOs: 38, 39, and 40. 5. A method of treating a CS1-expressing cancer comprising administering to a patient in need thereof a pharmaceutical composition comprising a population of human T cells expressing the CAR or polypeptide of claim 1 . 6. The method of claim 5 wherein the population of human T cells are autologous to the patient. 7. The method of claim 5 wherein the population of human T cells are allogenic to the patient. 8. The method of claim 5 , wherein the human T cells are prepared by a method comprising obtaining T cells from the patient or obtaining T cells allogenic to the patient, isolating from the obtained T cells a population of cells enriched for CD4+/CD8+ central memory T cells, and transducing at least a portion of the isolated population of cells to with a viral vector encoding a chimeric antigen receptor or polypeptide, wherein chimeric antigen receptor or polypeptide comprising the amino acid sequence of any of SEQ ID NOs: 29, 30, 31, 32, 33, 34, 38, 39, and 40. 9. The method of claim 5 , wherein the cancer is multiple myeloma.
Assignees
Inventors
Classifications
Chimeric antigen receptors [CAR] · CPC title
Cancer antigens · CPC title
T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title
- C07K14/70521Primary
CD28, CD152 · CPC title
Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK] · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11730797B2 cover?
- Chimeric antigen receptors for use in treating malignant melanoma and other cancers expressing CS1 are described.
- Who is the assignee on this patent?
- Hope City
- What technology area does this patent fall under?
- Primary CPC classification C07K14/70521. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Aug 22 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 5 related publications on this page (citations in our corpus or others sharing the same primary CPC).